279 related articles for article (PubMed ID: 29387578)
1. Fumaric acid esters in the management of psoriasis.
Balak DM
Psoriasis (Auckl); 2015; 5():9-23. PubMed ID: 29387578
[TBL] [Abstract][Full Text] [Related]
2. Fumaric acid esters for psoriasis: a systematic review.
Smith D
Ir J Med Sci; 2017 Feb; 186(1):161-177. PubMed ID: 27271164
[TBL] [Abstract][Full Text] [Related]
3. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus.
Mrowietz U; Barker J; Boehncke WH; Iversen L; Kirby B; Naldi L; Reich K; Tanew A; van de Kerkhof PCM; Warren RB
J Eur Acad Dermatol Venereol; 2018 Oct; 32 Suppl 3():3-14. PubMed ID: 30238510
[TBL] [Abstract][Full Text] [Related]
4. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. German Multicentre Study.
Mrowietz U; Christophers E; Altmeyer P
Br J Dermatol; 1998 Mar; 138(3):456-60. PubMed ID: 9580799
[TBL] [Abstract][Full Text] [Related]
5. Fumaric acid esters in severe psoriasis, including experience of use in combination with other systemic modalities.
Balasubramaniam P; Stevenson O; Berth-Jones J
Br J Dermatol; 2004 Apr; 150(4):741-6. PubMed ID: 15099371
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of fumaric acid esters in combination with phototherapy in patients with moderate-to-severe plaque psoriasis (FAST).
Weisenseel P; Reich K; Griemberg W; Merten K; Gröschel C; Gomez NN; Taipale K; Bräu B; Zschocke I
J Dtsch Dermatol Ges; 2017 Feb; 15(2):180-186. PubMed ID: 28214304
[TBL] [Abstract][Full Text] [Related]
7. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis.
Hoefnagel JJ; Thio HB; Willemze R; Bouwes Bavinck JN
Br J Dermatol; 2003 Aug; 149(2):363-9. PubMed ID: 12932244
[TBL] [Abstract][Full Text] [Related]
8. Fumaric acid esters for severe psoriasis: a retrospective review of 58 cases.
Harries MJ; Chalmers RJ; Griffiths CE
Br J Dermatol; 2005 Sep; 153(3):549-51. PubMed ID: 16120141
[TBL] [Abstract][Full Text] [Related]
9. Dimethyl fumarate (DMF) vs. monoethyl fumarate (MEF) salts for the treatment of plaque psoriasis: a review of clinical data.
Landeck L; Asadullah K; Amasuno A; Pau-Charles I; Mrowietz U
Arch Dermatol Res; 2018 Aug; 310(6):475-483. PubMed ID: 29574575
[TBL] [Abstract][Full Text] [Related]
10. Use of fumaric acid esters in psoriasis.
Roll A; Reich K; Boer A
Indian J Dermatol Venereol Leprol; 2007; 73(2):133-7. PubMed ID: 17456929
[TBL] [Abstract][Full Text] [Related]
11. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS).
Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K
Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526
[TBL] [Abstract][Full Text] [Related]
12. Long-term real-life safety profile and effectiveness of fumaric acid esters in psoriasis patients: a single-centre, retrospective, observational study.
Dickel H; Bruckner T; Altmeyer P
J Eur Acad Dermatol Venereol; 2018 Oct; 32(10):1710-1727. PubMed ID: 29705996
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and safety of fumaric acid esters in children with psoriasis: a retrospective analysis of 14 patients from The Netherlands.
Balak DM; Oostveen AM; Bousema MT; Venema AW; Arnold WP; Seyger MM; Thio HB
Br J Dermatol; 2013 Jun; 168(6):1343-7. PubMed ID: 23738641
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial.
Hamm H; Wilsmann-Theis D; Tsianakas A; Gambichler T; Taipale K; Lauterbach J; Freudensprung U; Makepeace C;
Br J Dermatol; 2021 Jul; 185(1):62-73. PubMed ID: 33332574
[TBL] [Abstract][Full Text] [Related]
15. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study.
Tzaneva S; Geroldinger A; Trattner H; Tanew A
Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862
[TBL] [Abstract][Full Text] [Related]
16. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE).
Pinter A; Hoffmann M; Reich K; Augustin M; Kaplan K; Gudjónsdóttir SD; Delvin T; Mrowietz U;
J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):701-711. PubMed ID: 32939860
[TBL] [Abstract][Full Text] [Related]
17. Fumaric acid esters in recalcitrant pediatric psoriasis: A prospective, daily clinical practice case series.
van Geel MJ; van de Kerkhof PC; Oostveen AM; de Jong EM; Seyger MM
J Dermatolog Treat; 2016; 27(3):214-20. PubMed ID: 26452994
[TBL] [Abstract][Full Text] [Related]
18. Fumaric acid esters for the treatment of psoriasis in Germany: characterising patients in routine care.
Mrowietz U; Sorbe C; Reich K; Von Kiedrowski R; Weckbecker J; Radtke MA; Rustenbach SJ; Augustin M
Eur J Dermatol; 2020 Feb; 30(1):41-48. PubMed ID: 32250255
[TBL] [Abstract][Full Text] [Related]
19. Progressive multifocal leukoencephalopathy associated with fumaric acid esters treatment in psoriasis patients.
Balak DMW; Hajdarbegovic E; Bramer WM; Neumann HAM; Thio HB
J Eur Acad Dermatol Venereol; 2017 Sep; 31(9):1475-1482. PubMed ID: 28322482
[TBL] [Abstract][Full Text] [Related]
20. Dimethyl Fumarate: A Review in Moderate to Severe Plaque Psoriasis.
Blair HA
Drugs; 2018 Jan; 78(1):123-130. PubMed ID: 29236231
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
